Biodel (NASDAQ: ALBO) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.
This is a breakdown of current ratings and target prices for Biodel and RegeneRx Biopharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Biodel and RegeneRx Biopharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Biodel||$11.36 million||19.78||-$4.03 million||N/A||N/A|
RegeneRx Biopharmaceuticals has lower revenue, but higher earnings than Biodel.
This table compares Biodel and RegeneRx Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Biodel has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. Comparatively, RegeneRx Biopharmaceuticals has a beta of -2.78, meaning that its share price is 378% less volatile than the S&P 500.
Institutional and Insider Ownership
29.2% of Biodel shares are owned by institutional investors. Comparatively, 0.2% of RegeneRx Biopharmaceuticals shares are owned by institutional investors. 22.3% of Biodel shares are owned by insiders. Comparatively, 12.1% of RegeneRx Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Biodel beats RegeneRx Biopharmaceuticals on 8 of the 11 factors compared between the two stocks.
Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company’s BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.
About RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.